The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Open accessAbstract
BACKGROUND AND OBJECTIVES: It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a higher remission rate, and maintaining the same safety profile compared with patients treated with RTX dosed at 1 g every 2 weeks. This hypothesis was supported by previous pharmacokinetic (PK) analysis showing that RTX levels in the two-dose regimen were 50% lower compared with nonproteinuric patients, which could potentially result in undertreatment. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Twenty patients with MN and proteinuria >5 g/24 h received RTX (375 mg/m(2) × 4), with re-treatment at 6 months regardless of proteinuria response. PK analysis was conducted simultaneously with immunological analyses of T and B cells to ascertain the effect of RTX on lymphocyte subpopulations. RESULTS: Baseline proteinuria of 11.9 g/24 h decreased to 4.2 and 2.0 g/24 h at 12 and 24 months, respectively, whereas creatinine clearance increased from 72.4 ml/min per 1.73 m(2) at baseline to 88.4 ml/min per 1.73 m(2) at 24 months. Of 18 patients who completed 24-month follow-up, 4 are in complete remission, 12 are in partial remission, 1 has a limited response, and 1 patient relapsed. Serum RTX levels were similar to those obtained with two doses of RTX. CONCLUSIONS: Four doses of RTX resulted in more effective B cell depletion, but proteinuria reduction was similar to RTX at 1 g every 2 weeks. Baseline quantification of lymphocyte subpopulations did not predict response to RTX therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Davis, T. A., Grillo-López, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., & Levy, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3135 · Cited by 687
Leandro, M. J., Cambridge, G., Ehrenstein, M. R., & Edwards, J. C. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21617 · Cited by 560
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
Anolik, J. H., Barnard, J., Cappione, A., Pugh‐Bernard, A. E., Felgar, R. E., Looney, R. J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20592 · Cited by 456
Sfikakis, P. P., Boletis, J., Lionaki, S., Vigklis, V., Fragiadaki, K., Iniotaki, A. G., & Moutsopoulos, H. Μ. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20858 · Cited by 410
Ponticelli, C., Zucchelli, P., Passerini, P., Cesana, B., Locatelli, F., Pasquali, S., Sasdelli, M., Redaelli, B., Grassi, C., Pozzi, C., et al. (1995) · Kidney International · doi:10.1038/ki.1995.453 · Cited by 407
Ponticelli, C., Altieri, P., Scolari, F., Passerini, P., Roccatello, D., Cesana, B., Melis, P., Valzorio, B., Sasdelli, M., Pasquali, S., et al. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v93444 · Cited by 389
Piro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A., Beck, T. M., Varns, C., Shuey, S., Czuczman, M., Lynch, J. W., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008389119525 · Cited by 368
Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial
Cattran, D. C., Appel, G. B., Hebert, L. A., Hunsicker, L. G., Pohl, M. A., Hoy, W. E., Maxwell, D. R., Kunis, C. L., & Syndrome, F. T. N. A. N. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590041484.x · Cited by 367
Self-citation
Cited by
Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis
Gomez Mendez, L. M., Cascino, M. D., Garg, J., Katsumoto, T. R., Brakeman, P., Dall’Era, M., Looney, R. J., Rovin, B., Dragone, L., & Brunetta, P. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01070118 · Cited by 188
Metadata
- Authors
- Fervenza, F. C., Abraham, R. S., Erickson, S. B., Irazabal, M. V., Eirin, A., Specks, U., Nachman, P. H., Bergstralh, E. J., Leung, N., Cosio, F. G., Hogan, M. C., Dillon, J. J., Hickson, L. J., Li, X., & Cattran, D. C.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2010-12
- Volume
- 5
- Issue
- 12
- Pages
- 2188-2198
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2122581834
- Cited by
- 299
- References
- 26
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study. https://app.cochat.ai/papers/10.2215/cjn.05080610
- The paper
- Fervenza, F. C., Abraham, R. S., Erickson, S. B., Irazabal, M. V., Eirin, A., Specks, U., Nachman, P. H., Bergstralh, E. J., Leung, N., Cosio, F. G., Hogan, M. C., Dillon, J. J., Hickson, L. J., Li, X., & Cattran, D. C. (2010). Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.05080610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
